Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab plus Chemotherapy in First-line HER2 Positive Advanced Biliary Tract Cancer
NCT07062263Phase 3Recruiting
- Sponsor
- Tata Memorial Centre
- Start
- Jul 2023
- Primary completion
- Jul 2029
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of trastuzumab in biliary tract cancer (BTC), sponsored by Tata Memorial Centre. Started Jul 2023; status: recruiting.
02
Drugs
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT07062263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07062263.